Clinical trial · Interventional
Feasibility and Efficacy of Interval Walking in Patients With Colorectal Cancer
I-Walk-CRC - Feasibility and Efficacy of Interval Walking in Patients With Colorectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Background: The level physical exercise is strongly associated with colorectal cancer risk in the general population, and recent data shows that physical activity after a colorectal cancer diagnosis is inversely associated with mortality risk, indication the physical exercise can protect against disease progression. However, few studies have successfully performed exercise interventions in patients with colorectal cancer, and the potential mechanisms responsible for the tumor suppressing effects of exercise remain poorly explored. Purpose: To investigate interval-walking, delivered by the InterWalk smart phone application as exercise-modality in patients with colorectal cancer. Specifically it is the aim to explore if InterWalk is safe and feasible as well as effective to improve cardio-metabolic health profile. Subjects: Colorectal cancer patients, stage I-III, who are at least one month post-surgery and have concluded any adjuvant chemotherapy treatment, are eligible for inclusion. Exclusion criteria are: age \<18; any major surgical procedure planned within 6 months after inclusion; pregnancy; ongoing treatment for any known malignancy; performance status \> 1; unable to read and understand Danish Methods: 40 colorectal cancer patients are included and randomized to I) InterWalk or II) waiting list control for 24 weeks. Patients are evaluated at baseline, week 12 and week 24 by assessment measures to determine cardio-metabolic health profile and other relevant study outcomes, including: cardiopulmonary exercise test (VO2peak); anthropometrics; blood pressure; resting heart rate; body composition; health related quality of life questionnaires; plasma concentration levels of cholesterol, triglycerides, insulin, glucose and inflammatory cytokines; insulin sensitivity; and cognitive function.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| InterWalk | Behavioral | — | UNRESOLVED |
| Waiting list control | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- InterWalk
- description
- The intervention program will prescribe that patients performing 150 min of interval training per week.
- interventionNames
- Behavioral: InterWalk
- type
- OTHER
- label
- Waiting list Control
- description
- Patients allocated to the waiting-list control group will receive usual care control for the first 12 weeks of the study and will receive the same instructions for download and use of the InterWalk app in the final 12 weeks.
- interventionNames
- Behavioral: Waiting list control
Primary outcomes (1)
- measure
- Change in VO2peak
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a verified stage I-III CRC diagnosis who has * All surgical and oncological treatments must be terminated Exclusion Criteria: * Any major surgical procedure planned within 6 months after inclusion * Pregnancy * Ongoing treatment for any known current malignancy * Performance status \> 1 * Inability to read and understand Danish * Physically active for more than 150 minutes (moderate intensity) per week thus adhering to the current recommendations
References
Publications (1)
- DERIVEDChristensen JF, Sundberg A, Osterkamp J, Thorsen-Streit S, Nielsen AB, Olsen CK, Djurhuus SS, Simonsen C, Schauer T, Ellingsgaard H, Osterlind K, Krarup PM, Mosgaard C, Vistisen K, Tolver A, Pedersen BK, Hojman P. Interval Walking Improves Glycemic Control and Body Composition After Cancer Treatment: A Randomized Controlled Trial. J Clin Endocrinol Metab. 2019 Sep 1;104(9):3701-3712. doi: 10.1210/jc.2019-00590. PMID 31220283